Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Jun 18, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Jun 18, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-issuer
Related Tickers: IPHA
TL;DR
Innate Pharma (IPHA) filed a 6-K, standard foreign issuer report, no new material info here.
AI Summary
On June 18, 2024, Innate Pharma SA filed a Form 6-K, reporting its status as a foreign private issuer. The filing includes an exhibit index, but the specific contents of the exhibits are not detailed in this header document. Innate Pharma SA is incorporated in France and its fiscal year ends on December 31.
Why It Matters
This filing indicates ongoing reporting requirements for Innate Pharma SA as a foreign private issuer, which is standard for companies listed on US exchanges but based internationally.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new material financial or operational information.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- 001-39084 (company) — SEC File Number
- 241050195 (company) — Film Number
- June 18, 2024 (date) — Date of Report
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to submit information that the company has made or is required to make public in its home country.
What is Innate Pharma SA's fiscal year end?
Innate Pharma SA's fiscal year ends on December 31.
Where is Innate Pharma SA's principal executive office located?
Innate Pharma SA's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Does Innate Pharma SA file an annual report under Form 20-F?
Yes, Innate Pharma SA indicates it files or will file annual reports under cover of Form 20-F.
What is the SIC code for Innate Pharma SA?
The Standard Industrial Classification (SIC) code for Innate Pharma SA is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 206 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-06-18 07:43:20
Filing Documents
- a6k-iphx240618.htm (6-K) — 9KB
- exhibit991-240618.htm (EX-99.1) — 17KB
- 0001598599-24-000049.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date June 18, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive officer